"Orange Book" Ratings In Labeling Would Lead To Medication Errors - PhRMA
Executive Summary
FDA's proposed use of "Orange Book" therapeutic ratings in labeling for generic drugs will lead to mistakes in dispensing and possible medication errors, the Pharmaceutical Research & Manufacturers of America said in comments to the agency.
You may also be interested in...
Generic Drug Label Reference To Brand Product Is Legally Allowed, FDA Says
Generic drug labels may now refer to the brandname product to which the product is therapeutically equivalent, FDA concluded in a draft guidance issued Jan. 28.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials